Fabry Disease - Epidemiology Forecast to 2028

Publisher Name :
Date: 15-Jan-2019
No. of pages: 50
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Fabry Disease - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the Fabry Disease epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered

- United States

- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

- Japan

Study Period: 2016-2028

Fabry Disease Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for Fabry Disease in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders' views are also taken into account to provide a deep understanding of the Fabry Disease outlook. It also includes the explanation of changing trends of epidemiology outlining the Fabry Disease scenario.

Fabry Disease Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Fabry Disease thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope

- The report covers detailed overview of Fabry Disease explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

- It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan

- The Fabry Disease Report assesses the disease risk and burden and highlights the unmet needs

- It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths

- 10 Year Forecast

- 7MM Coverage

- Total Cases in Fabry Disease

Key assessments

- Patient Segmentation in Fabry Disease

- Fabry Disease Risk & Burden

- Factors driving growth in a specific Fabry Disease patient population

Fabry Disease - Epidemiology Forecast to 2028

Table of Contents

1. Report Introduction
2. Fabry Disease Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Fabry Disease in 2016
2.2. Patient Share Distribution of Fabry Disease in 2028
3. Disease Background and Overview: Fabry Disease
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Fabry Disease in 7MM
4.3. Total Prevalent/ Incident Patient Population of Fabry Disease in 7MM - By Countries
5. Epidemiology of Fabry Disease by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Fabry Disease
5.1.3. Sub-Type Specific cases of the Fabry Disease *
5.1.4. Sex- Specific Cases of the Fabry Disease *
5.1.5. Diagnosed Cases of the Fabry Disease
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Fabry Disease
5.4.3. Sub-Type Specific cases of the Fabry Disease *
5.4.4. Sex- Specific Cases of the Fabry Disease *
5.4.5. Diagnosed Cases of the Fabry Disease
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Fabry Disease
5.5.3. Sub-Type Specific cases of the Fabry Disease *
5.5.4. Sex- Specific Cases of the Fabry Disease *
5.5.5. Diagnosed Cases of the Fabry Disease
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Fabry Disease
5.6.3. Sub-Type Specific cases of the Fabry Disease *
5.6.4. Sex- Specific Cases of the Fabry Disease *
5.6.5. Diagnosed Cases of the Fabry Disease
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Fabry Disease
5.7.3. Sub-Type Specific cases of the Fabry Disease *
5.7.4. Sex- Specific Cases of the Fabry Disease *
5.7.5. Diagnosed Cases of the Fabry Disease
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Fabry Disease
5.8.3. Sub-Type Specific cases of the Fabry Disease *
5.8.4. Sex- Specific Cases of the Fabry Disease *
5.8.5. Diagnosed Cases of the Fabry Disease
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Fabry Disease
5.9.3. Sub-Type Specific cases of the Fabry Disease *
5.9.4. Sex- Specific Cases of the Fabry Disease *
5.9.5. Diagnosed Cases of the Fabry Disease
6. Unmet Needs of the Fabry Disease
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Fabry Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Fabry Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Fabry Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Fabry Disease in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Fabry Disease in United States (2016-2028)*
Table 6: Diagnosed Cases of the Fabry Disease in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Fabry Disease in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Fabry Disease in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Fabry Disease in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Fabry Disease in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Fabry Disease in France (2016-2028)
Table 12: Sub-Type Specific cases of the Fabry Disease in France (2016-2028) *
Table 13: Sex- Specific Cases of the Fabry Disease in France (2016-2028) *
Table 14: Diagnosed Cases of the Fabry Disease in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Fabry Disease in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Fabry Disease in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Fabry Disease in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Fabry Disease in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Fabry Disease in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Fabry Disease in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Fabry Disease in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Fabry Disease in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Fabry Disease in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Fabry Disease in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Fabry Disease in UK (2016-2028) *
Table 26: Diagnosed Cases of the Fabry Disease in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Fabry Disease in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Fabry Disease in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Fabry Disease in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Fabry Disease in Japan (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Fabry Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Fabry Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Fabry Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Fabry Disease in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Fabry Disease in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Fabry Disease in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Fabry Disease in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Fabry Disease in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Fabry Disease in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Fabry Disease in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Fabry Disease in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Fabry Disease in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Fabry Disease in France (2016-2028) *
Figure 14: Diagnosed Cases of the Fabry Disease in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Fabry Disease in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Fabry Disease in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Fabry Disease in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Fabry Disease in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Fabry Disease in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Fabry Disease in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Fabry Disease in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Fabry Disease in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Fabry Disease in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Fabry Disease in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Fabry Disease in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Fabry Disease in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Fabry Disease in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Fabry Disease in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Fabry Disease in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Fabry Disease in Japan (2016-2028)

  • Familial Amyloid Neuropathies Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    Published: 28-Dec-2022        Price: US 2000 Onwards        Pages: 59
    Familial Amyloid Neuropathies Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Familial Amyloid Neuropathies - Drugs In Development, 2022, provides an overview of the Familial Amyloid Neuropathies (Metabolic Disorders) pipeline landscape. Familial amyloid neuropathy is a slowly progressive condition characterized by the bui......
  • Hyperglycemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    Published: 28-Dec-2022        Price: US 2000 Onwards        Pages: 35
    Hyperglycemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperglycemia - Drugs In Development, 2022, provides an overview of the Hyperglycemia (Metabolic Disorders) pipeline landscape. Hyperglycemia is a condition that occurs when blood glucose levels get too high. Several factors can contribute to hyperglycemia, incl......
  • Hyperinsulinemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    Published: 28-Dec-2022        Price: US 2000 Onwards        Pages: 54
    Hyperinsulinemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperinsulinemia - Drugs In Development, 2022, provides an overview of the Hyperinsulinemia (Metabolic Disorders) pipeline landscape. Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of......
  • Pituitary ACTH Hypersecretion (Cushing Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    Published: 28-Dec-2022        Price: US 2000 Onwards        Pages: 37
    Pituitary ACTH Hypersecretion (Cushing Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pituitary ACTH Hypersecretion (Cushing Disease) - Drugs In Development, 2022, provides an overview of the Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline landscape. Cushing's disease is a condition......
  • Diabetic Foot Ulcers Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    Published: 31-Oct-2022        Price: US 2000 Onwards        Pages: 142
    Diabetic Foot Ulcers Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers - Drugs In Development, 2022, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape. Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptom......
  • Diabetic Neuropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    Published: 31-Oct-2022        Price: US 2000 Onwards        Pages: 94
    Diabetic Neuropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy - Drugs In Development, 2022, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape. Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pa......
  • Diabetic Retinopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    Published: 31-Oct-2022        Price: US 2500 Onwards        Pages: 286
    Diabetic Retinopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Retinopathy - Drugs In Development, 2022, provides an overview of the Diabetic Retinopathy (Metabolic Disorders) pipeline landscape. Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may inclu......
  • Type 1 Diabetes (Juvenile Diabetes) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    Published: 31-Oct-2022        Price: US 2500 Onwards        Pages: 548
    Type 1 Diabetes (Juvenile Diabetes) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Drugs In Development, 2022, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline landscape. Type 1 diabetes (T1D) is an autoimmune disease in which a pancreas s......
  • Type 2 Diabetes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    Published: 31-Oct-2022        Price: US 2500 Onwards        Pages: 1127
    Type 2 Diabetes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 2 Diabetes - Drugs In Development, 2022, provides an overview of the Type 2 Diabetes (Metabolic Disorders) pipeline landscape. Type 2 diabetes is a chronic condition and is the most common form of diabetes. High levels of glucose are a characteristic feat......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs